Skip to main content
. 2018 Aug 28;8:305. doi: 10.3389/fonc.2018.00305

Figure 1.

Figure 1

Treatment course (Bev, bevacizumab; Iri, irinotecan; PMAb, panitumumab; LN, lymph node; Tissue NGS, tissue next generation sequencing; Guardant360, cell free DNA profiling; Cabo, cabozantinib).